New York 2025-2026 Regular Session

New York Senate Bill S06758

Introduced
3/24/25  
Refer
3/24/25  
Refer
1/7/26  
Engrossed
5/29/26  

Caption

Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.

Impact

The legislation aims to improve public health outcomes by mandating discussions about addiction risks, overdose potential, and alternative treatments. Practitioners will be required to counsel patients before initial and subsequent opioid prescriptions, emphasizing the consideration of non-opioid alternatives. This requirement aligns with current public health priorities aimed at combating the opioid epidemic and promoting safer pain management practices.

Summary

Bill S06758 mandates that healthcare practitioners discuss certain risks with patients before prescribing schedule II controlled substances or opioid analgesics. The bill reflects an ongoing effort to address the opioid crisis by ensuring that patients are adequately informed about the addictive nature of these drugs and the potential dangers involved in their use. This measure aims to enhance prescriber accountability and mitigate risks associated with opioid prescriptions.

Contention

While the bill is largely supported as a necessary measure to curb opioid misuse, some healthcare providers express concern about the additional regulatory burden it imposes. Critics argue that the bill may unintentionally complicate timely patient care for those with legitimate pain management needs. Additionally, the provision requiring discussions might lead to inconsistencies in counseling practices depending on individual practitioners’ interpretations of the bill, which could affect patient compliance and outcomes.

Companion Bills

NY A09010

Same As Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.

Previously Filed As

NY A09010

Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.

NY HB364

Opioids; require health care professionals to discuss opioid use prior to prescription of Schedule II controlled substances, exceptions provided

NY A289

Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven-day supply, except in certain circumstances.

NY S00493

Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.

NY A03116

Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.

NY S07508

Requires health care professionals to prescribe opioid antagonists when prescribing an opioid and discuss the dangers of opioid addiction with such patient in a manner consistent with regulations promulgated by the commissioner of health.

NY SB27

Controlled dangerous substances; exempting certain practitioners from electronic prescription requirement. Effective date.

NY SB27

Controlled dangerous substances; exempting certain practitioners from electronic prescription requirement. Effective date.

NY HB956

Opioid drugs; prescriber shall discuss with patient before prescribing, the risks of the drugs and available alternatives.

NY S00732

Relates to prescribing opioids to a minor; prohibits practitioners from prescribing to a minor more than a seven day supply of any controlled substance containing an opioid; requires practitioners to obtain written parental consent before issuing a first prescription of a controlled substance containing an opioid to a minor; establishes exceptions.

Similar Bills

AZ HB2944

Inpatient treatment days; computation; exclusion

AZ SB1244

Court-ordered treatment; continuation

CA AB1879

Substance use: treatment or residential data reporting.

AZ HB2706

Mental health; intensive treatment orders

CA AB2538

Medi-Cal: hospice providers: forms.

IA HF518

A bill for an act establishing a veterans recovery pilot program and fund for the reimbursement of expenses related to providing hyperbaric oxygen treatment to eligible veterans and making appropriations.(Formerly HF 326.)

IA HF326

A bill for an act establishing a veterans recovery pilot program and fund for the reimbursement of expenses related to providing hyperbaric oxygen treatment to eligible veterans and making appropriations.(See HF 518.)

HI SB2292

Relating To Workers' Compensation Medical Treatment.